Abstract:Importance: An accurate blood test for Alzheimer disease (AD) could streamline the diagnostic workup and treatment of AD. Objective: To prospectively evaluate a clinically available AD blood test in primary care and secondary care using predefined biomarker cutoff values. Design, setting, and participants: There were 1213 patients undergoing clinical evaluation due to cognitive symptoms who were examined between February 2020 and January 2024 in Sweden. The biomarker cutoff values had been established in an independent cohort and were applied to a primary care cohort (n = 307) and a secondary care cohort (n = 300); 1 plasma sample per patient was analyzed as part of a single batch for each cohort. The blood test was then evaluated prospectively in the primary care cohort (n = 208) and in the secondary care cohort (n = 398); 1 plasma sample per patient was sent for analysis within 2 weeks of collection. Exposure: Blood tests based on plasma analyses by mass spectrometry to determine the ratio of plasma phosphorylated tau 217 (p-tau217) to non-p-tau217 (expressed as percentage of p-tau217) alone and when combined with the amyloid-β 42 and amyloid-β 40 (Aβ42:Aβ40) plasma ratio (the amyloid probability score 2 [APS2]). Main outcomes and measures: The primary outcome was AD pathology (determined by abnormal cerebrospinal fluid Aβ42:Aβ40 ratio and p-tau217). The secondary outcome was clinical AD. The positive predictive value (PPV), negative predictive value (NPV), diagnostic accuracy, and area under the curve (AUC) values were calculated. Results: The mean age was 74.2 years (SD, 8.3 years), 48% were women, 23% had subjective cognitive decline, 44% had mild cognitive impairment, and 33% had dementia. In both the primary care and secondary care assessments, 50% of patients had AD pathology. When the plasma samples were analyzed in a single batch in the primary care cohort, the AUC was 0.97 (95% CI, 0.95-0.99) when the APS2 was used, the PPV was 91% (95% CI, 87%-96%), and the NPV was 92% (95% CI, 87%-96%); in the secondary care cohort, the AUC was 0.96 (95% CI, 0.94-0.98) when the APS2 was used, the PPV was 88% (95% CI, 83%-93%), and the NPV was 87% (95% CI, 82%-93%). When the plasma samples were analyzed prospectively (biweekly) in the primary care cohort, the AUC was 0.96 (95% CI, 0.94-0.98) when the APS2 was used, the PPV was 88% (95% CI, 81%-94%), and the NPV was 90% (95% CI, 84%-96%); in the secondary care cohort, the AUC was 0.97 (95% CI, 0.95-0.98) when the APS2 was used, the PPV was 91% (95% CI, 87%-95%), and the NPV was 91% (95% CI, 87%-95%). The diagnostic accuracy was high in the 4 cohorts (range, 88%-92%). Primary care physicians had a diagnostic accuracy of 61% (95% CI, 53%-69%) for identifying clinical AD after clinical examination, cognitive testing, and a computed tomographic scan vs 91% (95% CI, 86%-96%) using the APS2. Dementia specialists had a diagnostic accuracy of 73% (95% CI, 68%-79%) vs 91% (95% CI, 88%-95%) using the APS2. In the overall population, the diagnostic accuracy using the APS2 (90% [95% CI, 88%-92%]) was not different from the diagnostic accuracy using the percentage of p-tau217 alone (90% [95% CI, 88%-91%]). Conclusions and relevance: The APS2 and percentage of p-tau217 alone had high diagnostic accuracy for identifying AD among individuals with cognitive symptoms in primary and secondary care using predefined cutoff values. Future studies should evaluate how the use of blood tests for these biomarkers influences clinical care.

Should Alzheimer's be diagnosed without symptoms? Proposal to rely on blood tests roils scientists

Biomarker-only diagnosis of Alzheimer's disease: Not ready for prime time

Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease

Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?

Challenges in a Biological Definition of Alzheimer Disease

Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum

Clinical and Research Value of the New Diagnostic Criteria for Alzheimer's Disease.

Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings

[Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer's Dementia]

Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era

Translating blood biomarkers into clinical practice for Alzheimer's disease: Challenges and perspectives

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

A critical appraisal of blood-based biomarkers for Alzheimer's disease

Blood-based biomarkers in Alzheimer's disease – moving towards a new era of diagnostics

Blood‐based Biomarkers of Alzheimer's Disease: Standardization and Comprehensiveness

Alzheimer's disease biomarkers and their current use in clinical research and practice

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

Blood biomarkers for Alzheimer's disease in clinical practice and trials

Alzheimer Disease as a Clinical-Biological Construct

Current research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force